Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Biden announces $4B to support global vaccinations worldwide

By Sean Whooley | February 19, 2021

President Joe Biden announced that the U.S. is set to provide $4 billion to the COVAX Facility to support access to safe and effective COVID-19 vaccines.

Money appropriated by a December 2020 Congressional vote will comprise an initial $2 billion contribution to Gavi, the Vaccine Alliance for the COVAX advance market commitment (AMC) covering 92 low- and middle-income economies, according to a White House Statement.

Additionally, the U.S. will release a further $2 billion through 2021 and 2022, with the first $500 million set to be made available when existing donor pledges are fulfilled and initial doses are delivered to AMC countries.

Biden also called on the G7 and other partners to work alongside Gavi to continue to build support for global COVID-19 vaccination, targeting urgent vaccine manufacturing, supply and delivery needs.

“The United States’ contribution is designated to help Gavi prevent, prepare for, and respond to coronavirus through vaccine procurement and delivery for the world’s most vulnerable,” the White House statement read. “In partnership with Gavi, the bulk of these funds will be targeted to support direct vaccine procurement, and a portion will also support broader country readiness and vaccine service delivery.”

COVAX has been collecting pledges from a number of companies over the past several months, promising the delivery of vaccines to the AMC to reach the 92 low- and middle-income economies.

In October, Sanofi (NSDQ:SNY) and GSK (LON: GSK), which have teamed up to produce a COVID-19 vaccine candidate, vowed to produce 200 million doses of the vaccine for COVAX. That vaccine candidate is still in the midst of clinical trials and has not yet been authorized for use.

Since then, Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) said last month that they would supply up to 40 million doses of their COVID-19 vaccine this year to COVAX. In announcing a submission for emergency use listing (EUL) to the World Health Organization (WHO) today, Johnson & Johnson (NYSE:JNJ) said today that it had previously agreed on plans to enter into an advance purchase agreement for up to 500 million doses of the vaccine to be provided to COVAX through 2022.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson Merck COVID-19 vaccine
Biden announces partnership for Merck to make J&J’s COVID-19 vaccine
COVID-19 vaccine
Feds order 200M more vaccine doses from Pfizer, Moderna
Johnson & Johnson
J&J CEO says getting a COVID-19 vaccine could be an annual ritual for years
Merck
Merck KGaA to supply lipids to boost Pfizer-BioNTech COVID-19 vaccine production

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards